CN1394602A - 用于治疗动脉粥样硬化的苯甲酸取代的苯并吡喃 - Google Patents

用于治疗动脉粥样硬化的苯甲酸取代的苯并吡喃 Download PDF

Info

Publication number
CN1394602A
CN1394602A CN02125125A CN02125125A CN1394602A CN 1394602 A CN1394602 A CN 1394602A CN 02125125 A CN02125125 A CN 02125125A CN 02125125 A CN02125125 A CN 02125125A CN 1394602 A CN1394602 A CN 1394602A
Authority
CN
China
Prior art keywords
treating atherosclerosis
compound
benzyl
carboxy
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN02125125A
Other languages
English (en)
Chinese (zh)
Inventor
罗伯特·J·艾洛
帕特里夏－安·布拉萨
萨拉林·林赛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1394602A publication Critical patent/CN1394602A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN02125125A 2001-06-28 2002-06-28 用于治疗动脉粥样硬化的苯甲酸取代的苯并吡喃 Pending CN1394602A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30171201P 2001-06-28 2001-06-28
US60/301,712 2001-06-28
US32825401P 2001-10-10 2001-10-10
US60/328,254 2001-10-10

Publications (1)

Publication Number Publication Date
CN1394602A true CN1394602A (zh) 2003-02-05

Family

ID=26972559

Family Applications (1)

Application Number Title Priority Date Filing Date
CN02125125A Pending CN1394602A (zh) 2001-06-28 2002-06-28 用于治疗动脉粥样硬化的苯甲酸取代的苯并吡喃

Country Status (12)

Country Link
EP (1) EP1270000A3 (enExample)
JP (1) JP2003034638A (enExample)
KR (1) KR20030015828A (enExample)
CN (1) CN1394602A (enExample)
AU (1) AU4239302A (enExample)
CA (1) CA2391205A1 (enExample)
CZ (1) CZ20022076A3 (enExample)
HK (1) HK1049795A1 (enExample)
HU (1) HUP0202114A3 (enExample)
IL (1) IL150340A0 (enExample)
PL (1) PL354770A1 (enExample)
SK (1) SK8682002A3 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4476934B2 (ja) * 2003-04-14 2010-06-09 明治乳業株式会社 新規ペプチドおよび免疫賦活剤、機能性食品ならびに機能性食品の製造方法
KR20070035101A (ko) * 2004-07-22 2007-03-29 파마시아 코포레이션 Ｃｏｘ-2 선택적 억제제 및 ｌｔｂ4 수용체 길항제의조합을 이용한 염증 및 통증 치료 조성물
JP5846711B2 (ja) * 2005-06-09 2016-01-20 メダ アーベー 炎症性疾患の治療のための方法及び組成物
US10336733B2 (en) 2015-11-30 2019-07-02 Merk Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
EP3383389B1 (en) 2015-11-30 2021-04-28 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as blt1 antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720493A1 (de) * 1987-06-20 1989-01-26 Nattermann A & Cie Arzneizubereitungen mit mikronisierten ebselen-kristallen
MX9300312A (es) * 1992-01-23 1993-07-31 Pfizer Antagonistas benzopiranicos y relacionado de ltb.
DE4228200A1 (de) * 1992-08-25 1994-03-03 Schering Ag Neue Pyridin-Derivate mit Leukotrien-B¶4¶-antagonistischer Wirkung
CN1160399A (zh) * 1994-10-13 1997-09-24 美国辉瑞有限公司 苯并吡喃和苯并稠合化合物、其制备方法和它们作为白三烯b4(ltb4)拮抗剂的用途
KR100232340B1 (ko) * 1994-10-13 1999-12-01 디. 제이. 우드, 스피겔 알렌 제이 류코트리엔 b4(ltb4) 길항물질로서의 벤조피란 및 벤조-축합된 화합물
CA2224563A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
DE19636689A1 (de) * 1996-09-10 1998-03-12 Boehringer Ingelheim Kg Neue Benzamidinderivate
JP3117730B2 (ja) * 1996-09-16 2000-12-18 ファイザー・インク 置換クロマール誘導体を製造するための方法及び中間体
EP0963755A3 (en) * 1998-04-16 2001-03-14 Pfizer Products Inc. Use of benzopyranes for preventing allograft rejection
AU5687199A (en) * 1998-08-24 2000-03-14 Global Vascular Concepts, Inc. Use of anti-angiogenic agents for inhibiting vessel wall injury
JP2003225088A (ja) * 1999-09-10 2003-08-12 Meiji Seika Kaisha Ltd ヒト・ロイコトリエンｂ４第二受容体及びそれをコードするｄｎａ
EP1268777A2 (en) * 2000-03-17 2003-01-02 Bayer Aktiengesellschaft Regulation of human leukotriene b 4?-like g protein-coupled receptor

Also Published As

Publication number Publication date
HU0202114D0 (enExample) 2002-09-28
CZ20022076A3 (cs) 2004-05-12
HK1049795A1 (zh) 2003-05-30
HUP0202114A2 (hu) 2003-01-28
KR20030015828A (ko) 2003-02-25
SK8682002A3 (en) 2004-08-03
AU4239302A (en) 2003-01-02
PL354770A1 (en) 2002-12-30
EP1270000A2 (en) 2003-01-02
EP1270000A3 (en) 2003-02-12
JP2003034638A (ja) 2003-02-07
IL150340A0 (en) 2002-12-01
HUP0202114A3 (en) 2004-07-28
CA2391205A1 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
CN1116288C (zh) 用作肌苷－5'－一磷酸脱氢酶抑制剂的脲衍生物
CN1196687C (zh) Impdh酶抑制剂
CN1028992C (zh) 1，4，-苯并硫杂吖庚因衍生物的制备方法
CN1680367A (zh) 取代的2－（2,6－二氧哌啶－3－基)－邻苯二甲酰亚胺和－1－氧异二氢吲哚及降低肿瘤坏死因子α水平的方法
CN1520290A (zh) 含铜胺氧化酶的碳环肼基抑制剂
CN1348436A (zh) 新颖的核受体ppar配体
CN1653125A (zh) 白内障和其它眼病发展的改善
CN1062138A (zh) Hiv反转录酶抑制剂的增效
CN1048014C (zh) 取代的吡咯类化合物及其制法、药物组合物和用途
CN112513011A (zh) 苯衍生物
HK1049795A1 (zh) 用於治疗动脉粥样硬化的苯甲酸取代的苯并吡喃
CN1113386A (zh) 取代的犬尿氨酸、其制备方法及其作为药物的用途
CN1100301A (zh) 用于神经保护的药物
CN1914149A (zh) 用于治疗处于血栓形成心血管事件危险中的患者的环氧合酶－2为媒的疾病或状况的组合治疗
CN1254243C (zh) 包含白屈菜碱或其衍生物的药物组合物
FR2796641A1 (fr) Nouveau procede de preparation de composes benzoperhydroisoindole
CN1042354A (zh) (RS)-2-(2，3-二氢-5-羟基-4，6，7-三甲苯氧茚基)乙酸和2-2，3-二氢-5-乙酰氧基-4，6，7-三甲基氧茚基)乙酸及其酯，用作粘液调节剂和抗hyschaemic药物及其制备方法
CN104844533A (zh) 含五元芳杂环的氨基丙二醇类化合物、其制备方法及其医药用途
JPH11501655A (ja) ２，３−ジヒドロ−ベンゾフラノール誘導体の新規な製造法
CN1528745A (zh) 吡咯烷类基质金属蛋白酶抑制剂及其制备方法
CN1138852A (zh) 哒嗪酮衍生物
CN1914169A (zh) 作为环氧合酶－2抑制剂的二芳基－2－(5h)－呋喃酮的氧化氮释放前药
CN1124484A (zh) 3-(吲哚-3-基)丙烯酸衍生物及其用作nmda拮抗剂
CN1422852A (zh) 取代六元氮杂环类化合物及其作为神经调节剂的用途
CN1974554A (zh) 环酰亚胺类肽金属蛋白酶抑制剂及其应用

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1049795

Country of ref document: HK